Agree that idiosyncratic hepatotoxicity in TRO-treated patients is uncertain, but concerned about the data.
Kostrubsky
Vsevolod E
VE
Rahbari
Ramin
R
Lodola
Alberto
A
Davies
Thomas
T
D017209:Apoptosis / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002839:Chromans / Q000633:toxicity*; D016572:Cyclosporine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004336:Drug Antagonism; D022781:Hepatocytes / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D006801:Humans; D007004:Hypoglycemic Agents / Q000633:toxicity*; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000648:ultrastructure; D013844:Thiazoles / Q000633:toxicity*; D045162:Thiazolidinediones; D000077288:Troglitazone; D014407:Tumor Cells, Cultured
D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D016572:Cyclosporine; D000077288:Troglitazone